Why Half of People Quit Weight Loss Medication — And How to Stay on Track

A 2026 analysis of UK prescribing data found that roughly half of adults using GLP-1 weight loss medications privately had discontinued within 12 months, with cost cited as the single most common reason. This is not a failure of the medication — it is a failure of support, planning, and access. Understanding why people stop, and what genuinely helps them continue, is one of the most important conversations in weight management today.

Weight loss injections such as Mounjaro (tirzepatide) and Wegovy (semaglutide) have transformed the landscape of medically supported weight management in the UK. Clinical trials have demonstrated average body weight reductions of up to 22% with tirzepatide and around 15% with semaglutide — results that were previously only associated with bariatric surgery. And yet, despite this remarkable efficacy, a significant number of people stop treatment within their first year.

The Adherence Problem: Why So Many People Stop

The dominant reason people discontinue weight loss injections is straightforward: they are expensive. Unlike NHS prescriptions that carry a flat charge (or are free for many patients), private GLP-1 medications carry a significant monthly cost. Following Eli Lilly's September 2025 UK price increase, Mounjaro's highest dose rose to £300 per month — an increase of over 170% from its original launch price. For many households, that simply is not sustainable over the course of a full treatment programme.

But cost is not the only barrier. Side effects — particularly nausea, fatigue and gastrointestinal discomfort — are most pronounced in the early weeks of treatment, precisely the period when patients are still building confidence in the medication. Without clear clinical guidance about what to expect and how to manage these symptoms, it is easy for someone to interpret early discomfort as a reason to stop rather than a temporary phase to get through.

Weight loss plateaus are another common trigger for discontinuation. Between months three and six, many patients experience a natural slowdown in the rate of weight reduction. Without advance preparation and support, this plateau can feel like the treatment has stopped working — particularly if expectations were set unrealistically high at the outset.

Finally, there is the underappreciated issue of perceived success. Some patients feel so much better — their appetite is reduced, their weight is moving in the right direction — that they decide to stop early, believing they no longer need the support. Research consistently shows that weight regain following discontinuation of GLP-1 medications is common and can be rapid, particularly without accompanying lifestyle changes.

Common Reasons for Stopping Weight Loss Injections — and What Helps

What the Evidence Says About Staying on Treatment

A landmark study published in the New England Journal of Medicine demonstrated clearly what happens when people stop semaglutide: within one year of discontinuation, participants regained an average of two-thirds of the weight they had lost. This finding underscores that weight loss injections are not a short-term fix — they are a medical treatment for a chronic condition, and stopping prematurely undermines the clinical benefit.

The NHS, through its phased rollout of Mounjaro via specialist weight management services and GP prescribing (from late 2025), is beginning to address the support gap for eligible patients. NICE guidance supports a 12-week review point to assess treatment response, with ongoing monitoring thereafter. However, the majority of people currently using Mounjaro and Wegovy in the UK are doing so privately — and this is where the quality of ongoing clinical support varies enormously.

A 2024 review in the British Medical Journal highlighted that patients planning structured lifestyle support and change alongside GLP-1 therapy had significantly better outcomes and higher rates of continued adherence than those receiving medication alone. The conclusion was clear: the injection is a tool, not a solution in isolation.

Practical Steps to Improve Your Chances of Long-Term Success

Whether you are just starting out with weight loss injections or you are a few months in and finding it harder to stay committed, there are practical, evidence-based steps that can make a real difference to your long-term results.

Plan for the early side effect phase

Nausea and digestive discomfort are most common in the first four to eight weeks of treatment, particularly after a dose increase. Eating smaller meals, avoiding fatty or heavily processed foods, and staying well hydrated can significantly reduce these symptoms. Most people find they improve substantially as their body adjusts. If side effects are severe or persistent, contact your prescriber — dose titration can be adjusted.

Set realistic expectations before you begin

Mounjaro and Wegovy produce meaningful, clinically significant weight loss — but not overnight. A weight loss of 0.5 to 1 kg per week is typical in the early months. Plateaus are normal, and they do not mean treatment has failed. Working with your clinical team to understand what to expect at each stage reduces the risk of premature discontinuation based on unrealistic timelines.

Build lifestyle changes in from the start

GLP-1 medications reduce appetite and help manage cravings — but they work best when combined with a nutritious diet and regular physical activity. NICE guidance is clear that lifestyle support should accompany prescribing. Patients who invest in both the medication and the lifestyle adjustment consistently achieve and maintain better results.

Have an honest conversation about cost at the outset

The long-term nature of treatment means monthly costs should be considered before starting. At Happy Pharmacy, our clinical team can discuss the full range of available doses and treatment approaches, helping patients understand what a realistic 12-month programme would involve and how to manage costs sustainably — including moving to lower maintenance doses once target weight is achieved.

Do not stop without speaking to your prescriber

If you are considering stopping treatment — whether due to cost, side effects, or a sense that it has done its job — please speak to your prescriber first. The risks of rapid weight regain following abrupt discontinuation are real, and in many cases, there are options to consider before stopping entirely, including dose reduction or a managed pause with monitoring.

Choosing a Provider You Can Trust

With over two million UK adults currently self-funding weight loss injections privately, the market has grown rapidly — and not always with patient safety at the forefront. The MHRA's October 2025 raid of a Northampton warehouse, uncovering counterfeit tirzepatide and unlicensed retatrutide pens, was a stark reminder of what is at stake when people buy from unregulated sources. Testing by ITV in November 2025 found social-media sourced pens containing the wrong active ingredient at up to 20 times the recommended starting dose — a genuinely life-threatening risk.

Choosing a GPhC-registered online pharmacy like Happy Pharmacy means your prescription is issued by a qualified, regulated prescriber following a thorough clinical consultation. Your medication is dispensed from a licensed facility. And your ongoing support comes from a team that is professionally accountable for your safety and results — not an anonymous website.

This matters especially for patients managing long-term treatment. Adherence is not just about personal motivation — it is directly shaped by the quality of the clinical environment around you. A trusted, personal relationship with your pharmacy team is one of the most powerful tools available for staying on track.

Final Thoughts

Weight loss injections like Mounjaro and Wegovy are genuinely transformative treatments for the right patients. The fact that so many people stop within a year is not an inevitable outcome — it is a solvable problem. With the right preparation, clinical support, realistic expectations, and a trusted provider, long-term adherence is achievable.

If you are considering starting weight loss injections, or if you have previously stopped and would like to explore restarting in a more supported way, Happy Pharmacy is here to help. Our online consultations are straightforward, our prescribing team is regulated and experienced, and our commitment to your long-term health — not just your first prescription — sets us apart.

References

1. IQVIA / UCL BMC Medicine (2026) — UK GLP-1 prescribing and adherence data: https://bmcmedicine.biomedcentral.com

2. NHS England — Wegovy NICE guidance for cardiovascular patients (April 2026): https://www.england.nhs.uk/2026/04/million-people-offered-wegovy-cut-heart-attack-stroke-risk/

3. NICE — Semaglutide for weight management (TA875): https://www.nice.org.uk/guidance/ta875

4. NICE — Tirzepatide for weight management (TA1026): https://www.nice.org.uk/guidance/ta1026

5. Wilding JPH et al. (2022) — Weight regain following semaglutide cessation, NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2204761

6. MHRA Drug Safety Update — GLP-1 pancreatitis alert (January 2026): https://www.gov.uk/drug-safety-update

7 National Pharmacy Association / YouGov (2026) — 3.3 million UK adults projected to use weight loss injections: https://www.npa.co.uk

8. British Medical Journal — Structured lifestyle support alongside GLP-1 therapy (2024): https://www.bmj.com

9. MHRA — Counterfeit tirzepatide seizure, Northampton (October 2025): https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

This blog is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Happy Pharmacy is registered with the General Pharmaceutical Council (GPhC). Registration details available at happypharmacy.co.uk.